DURHAM, N.C. – A treatment paradox has recently come to light in prostate cancer: Blocking testosterone production halts tumor growth in early disease, while elevating the hormone can delay disease ...

Metastatic castration-resistant prostate cancer (mCRPC) is a type of advanced prostate cancer that has spread to other parts of the body. It no longer responds to treatments that block testosterone, a ...

When Jim Morris was 67 years old, their doctor diagnosed them with prostate cancer and suggested that they undergo radiation treatment. The doctor also prescribed them medication to stop their body’s ...

For decades, a fundamental strategy for treating advanced prostate cancer has been to block testosterone, a male-associated hormone (or androgen) that drives the growth and spread of the malignancy.

Testosterone declines gradually, and the signs are easy to overlook or misinterpret. Here’s how doctors evaluate hormone levels and what to consider before pursuing therapy.

Share on Pinterest A new combination therapy for prostate cancer shows promise in clinical trials. Image credit: 1shot Production/Getty Images. A multinational, phase 3 clinical trial – TALAPRO-2 – ...